Floatz logo

BMS-986345

NK-Cell Lymphomas

Memorial Sloan Kettering Cancer CenterPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the NK-Cell Lymphomas cohort.

Asset / SponsorPhaseRating
Ruxolitinib
Memorial Sloan Kettering Cancer Center
Phase 1CC
Duvelisib
Memorial Sloan Kettering Cancer Center
Phase 1CC

Same molecule, other indications

BMS-986345 is also rated in:

Chronic Lymphocytic LeukemiaDormant
B
Indicative ·
58 / 100
View asset →
Follicular LymphomaDormant
B
Indicative ·
56 / 100
View asset →
Indolent Non-Hodgkin LymphomaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →